Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Prism Medico and Pharmacy Ltd, at its meeting held on 28 May 2025, approved the audited standalone financial results for the quarter and financial year ended 31 March 2025. Revenue from operations for FY25 collapsed sharply to Rs 63.19 lakhs compared to Rs 292.52 lakhs in FY24, a drop of roughly 78%. The company reported a net loss of Rs 4.87 lakhs for FY25, wider than the Rs 2.13 lakh loss in FY24, with cash losses of Rs 6.16 lakhs. However, Q4 FY25 (Jan–Mar 2025) showed a turnaround with a net profit of Rs 4.15 lakhs against a loss of Rs 6.76 lakhs in the previous quarter. The statutory auditor (Harjeet Parvesh & Co.) issued an unmodified (clean) opinion on the financial statements, and reported no fraud, no loan defaults, and no pending litigations impacting financial position.
Sharp revenue decline and widening annual losses are negative signals for shareholders, though the clean audit opinion and a small Q4 profit offer some reassurance. Stock sentiment may remain weak given the significant top-line contraction and the company being involved only in trading activities with unchanged inventory levels.